Datasheet: The Opto™ Antigen Presenting Bead Kit
Learn more about the Opto™ Antigen Presenting Bead (Opto™ APB) Kit, its key applications, and how it benefits your cell therapy development workflows by efficiently expanding more antigen-specific T cells than dendritic cells.
Brochure: Antibody Discovery
Find out how Opto™ Plasma B Discovery using the Beacon® optofluidic system accelerates lead molecule discovery against difficult targets.
Product Tour: The Opto™ Plasma B Discovery 4.0 Workflow
Antibody expert, Anupam Singhal, PhD, does a 10-minute walkthrough of how the Opto™ Plasma B Discover workflow makes it possible to accelerate lead molecule discovery against difficult targets.
Webinar: A Beacon for Rapid Antibody Discovery against Difficult Targets
Panelists from Genovac, will present case studies of how they have leveraged their core genetic immunization technology and the Beacon optofluidic system to rapidly discover antibodies against challenging targets, such as GPCRs, from a variety of different animal species.
Application Note: Unravel the Complexity of Single Natural Killer Cell Cytotoxicity and ADCC Mediation
Explore how the Cytotoxicity Assay can be used to characterize and better understand NK cells in the pursuit of more efficacious cell therapies.
Poster: Antigen Validation using Berkeley Lights Opto™ Antigen Presenting Bead Kit
Explore the data from the Opto Antigen Presenting Bead Kit and its ability to relieve a critical bottleneck in the tumor antigen discovery process.
Application Note: Rapid High-Resolution Screening of Plasma B Cells to Identify Antibody Lead Candidates
Explore case studies for the rapid discovery of antibodies against challenging targets.
Customer Spotlight: Abveris on Antibody Discovery
Find out how Abveris is transforming their antibody discovery processes with the Beacon® optofluidic system.
Datasheet: Cell Analysis Suite (CAS™) 2.1 Software
Review our premier software, its key applications, and the features exclusive to the 2.1 upgrade.
Application Note: Multidimensional Analysis of T Cell Cytotoxicity and Serial Killing Using the Opto™ Cell Therapy Development Workflow
Learn how to use multiple assays on single T cells to finally understand critical functions, such as serial killing, and how they relate to each other.
Application Note: Identify and Select Optimal CAR T Cell Phenotypes with the Opto™ Cell Therapy Development Workflow
Learn how to combine the T Cell Proliferation Assay with either the Multiplex Cytokine Assay or Cytotoxicity Assay to find your most persistent T cells.
Customer Spotlight: Amgen on AbD and CLD
Find out how Amgen is transforming their antibody discovery and clonal cell line processes with the Berkeley Lights Platform.
Webinar: Expand and Rapidly Validate Antigen-Specific Function of T Cells Using Fewer Cells
Yelena Bronevetsky, PhD, lays out the current challenges in tumor antigen discovery and how our Opto™ Antigen Presenting Bead Kit helps scientists overcome them.
Fireside Chat: Every Day Matters – Optimizing COVID-19 Therapies for Manufacturing
Dr. James Rothman, Nobel Laureate hosts an in-depth discussion with distinguished guests, Dr. Jennitte Stevens from Amgen, Dr. Gregory Bleck from Catalent-Biologics, and Dr. Trent Munro from the University of Queensland on fast-tracking the development of therapeutic antibodies and vaccines for SARS-CoV-2.
Customer Spotlight: Catalent on CLD
Find out how Catalent Biologics is able to select significantly higher expressing clonal cell lines with the Opto CLD workflow.
Product Tour: The Opto™ Cell Therapy Development Workflow
Guided by T cell expert, Yelena Bronevetsky, PhD, get a deeper look at how the Opto™ Cell Therapy Development workflow can be used to validate, expand, and fully characterize over a 1,000 T cells.
Application Note: Rapid Discovery of Therapeutic Antibodies for the SARS-CoV-2 Pandemic Virus Using the Opto Viral Neutralization 1.0 Workflow
Learn how to use blocking and binding assays and the Opto Viral Neutralization 1.0 workflow to identify cross-reactive antibodies that may have broad neutralization capacity across the coronavirus family.
Product Tour: The Opto™ CLD Workflow
Antibody expert, Anupam Singhal, PhD, does a 10-minute walkthrough of how the Opto™ CLD workflow makes it possible to produce superior cell lines, with >99% monoclonality assurance, in a matter of days.